Rheumatoid arthritis (RA) management has greatly improved with the development of biologic disease modifying antirheumatic drugs, but a proportion of patients do not improve despite the biologic drugs currently available. We need new biologic agents with novel mechanisms of action for the treatment of refractory patients. Recent evidence has shown that granulocyte-macrophage colony-stimulating factor (GM-CSF) is involved in the pathogenesis of RA. GM-CSF can exacerbate RA and elevated levels of this cytokine have been observed in synovial fluid from RA patients. Antagonism of GM-CSF can strikingly reduce established disease in mouse models of arthritis. Mavrilimumab, a human monoclonal antibody to GM-CSF receptor α, is a competitive antagonist of GM-CSF signaling. Phase I and II studies have shown good clinical response with a good safety profile in patients with mild to moderate RA, suggesting encouraging effects of mavrilimumab for the treatment of RA. This paper reviews the preclinical and clinical data evaluating the safety, tolerability, and efficacy of mavrilimumab in the treatment of RA. © 2014 Di Franco et al.

Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis / DI FRANCO, Manuela; Gerardi, MARIA CHIARA; Lucchino, Bruno; Conti, Fabrizio. - In: CORE EVIDENCE. - ISSN 1555-175X. - ELETTRONICO. - 9:(2014), pp. 41-48. [10.2147/ce.s39770]

Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis.

DI FRANCO, Manuela;GERARDI, MARIA CHIARA;LUCCHINO, BRUNO;CONTI, FABRIZIO
2014

Abstract

Rheumatoid arthritis (RA) management has greatly improved with the development of biologic disease modifying antirheumatic drugs, but a proportion of patients do not improve despite the biologic drugs currently available. We need new biologic agents with novel mechanisms of action for the treatment of refractory patients. Recent evidence has shown that granulocyte-macrophage colony-stimulating factor (GM-CSF) is involved in the pathogenesis of RA. GM-CSF can exacerbate RA and elevated levels of this cytokine have been observed in synovial fluid from RA patients. Antagonism of GM-CSF can strikingly reduce established disease in mouse models of arthritis. Mavrilimumab, a human monoclonal antibody to GM-CSF receptor α, is a competitive antagonist of GM-CSF signaling. Phase I and II studies have shown good clinical response with a good safety profile in patients with mild to moderate RA, suggesting encouraging effects of mavrilimumab for the treatment of RA. This paper reviews the preclinical and clinical data evaluating the safety, tolerability, and efficacy of mavrilimumab in the treatment of RA. © 2014 Di Franco et al.
2014
gm-csf; mavrilimumab; rheumatoid arthritis
01 Pubblicazione su rivista::01a Articolo in rivista
Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis / DI FRANCO, Manuela; Gerardi, MARIA CHIARA; Lucchino, Bruno; Conti, Fabrizio. - In: CORE EVIDENCE. - ISSN 1555-175X. - ELETTRONICO. - 9:(2014), pp. 41-48. [10.2147/ce.s39770]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/872339
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 18
  • ???jsp.display-item.citation.isi??? ND
social impact